 |
 |
Innofluor®
Fluorescence Polarization Immunoassays |
|
Intended Use
The INNOFLUOR® Assay Systems are intended for the quantitative determination of total drug in serum for therapeutic drug monitoring by fluorescence polarization immunoassay (FPIA). The assay system is for use on an FPIA capable analyzer.
Principles of Operation of the Innofluor Products
The INNOFLUOR® Assay Systems comprise fluorescence polarization immunoassays based on the competitive binding principle1. Sample antigen (drug) competes with fluorescein-labeled antigen for a fixed number of antibody binding sites. When linearly polarized light is used to excite the fluorescein-labeled antigen, which is small and rotates rapidly in solution, emitted light is significantly depolarized. When fluorescein-labeled antigen is bound to antibody, rotation is slowed and linearly polarized excitation light stays highly polarized upon emission. Increased amounts of unlabeled antigen in the sample will result in decreased binding of fluorescein-labeled antigen by antibody, and decreased polarization of emitted light from the sample. The concentration of antigen in an unknown can be determined by comparing the polarization value of the unknown sample against polarization values from a calibration curve established on FPIA capable analyzers.
|
|
|
|
|
